Vicore Pharma Holding AB (publ) (VCRE) Stock Price & Analysis
Vicore Pharma Holding AB (publ) (VCRE) closed at USD 9.09 on Thursday, October 15, 2026, up 0.11% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 9.08; the Oct 15, 2026 session ranged USD 8.93–9.3 on volume of 38,514 shares. Market capitalization is $256.01M, with a 52-week range of USD 7.88–17.8 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VCRE.md
Key facts (VCRE)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 29.25 (range 25.16–33.35).
- Total return with dividends: 1Y -44.1% vs S&P 500 +18.1%; 5Y -34.0% vs S&P 500 +85.1%.
Analysts (VCRE)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 29.25 (low 25.16, high 33.35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | Jefferies | Initiated | Buy | $25 |
Total return (dividends reinvested) (VCRE)
| 1Y (from 2026-07-06) | 5Y (from 2026-07-06) | |
|---|---|---|
| Total return | -44.1% | -34.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 47.4% | 42.6% |
| Max drawdown | -46.7% (Jul 2026→Oct 2026) | -34.7% (Jul 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 9.09 |
|---|---|
| Change | ▲ 0.11% (up) |
| Previous Close | USD 9.08 |
| Open | USD 9.02 |
| Day Range | USD 8.93 – 9.3 |
| 52-Week Range | USD 7.88 – 17.8 |
| Volume | 38,514 shares |
| Market Cap | $256.01M |
| Exchange | NCM |
Technical Analysis (VCRE)
Nexqual's technical model rates VCRE "STRONG SELL" based on 0 bullish and 5 bearish signals across 73 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.92 (neutral) |
| vs SMA50 | Below (USD 10.74) |
| MACD | -0.52 (negative) |
Analyst Ratings (VCRE)
Wall Street analysts rate VCRE "Buy" based on 2 analysts, with a mean price target of USD 29.25 (range USD 25.16–33.35), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 29.25 |
| High Target | USD 33.35 |
| Low Target | USD 25.16 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (VCRE)
| Revenue Estimate | $781,500 |
|---|
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (VCRE)
| Revenue Growth (latest quarter, YoY) | +26.70% |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -56.99% |
| Current Ratio | 12.68 |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (VCRE)
Nexqual rates Vicore Pharma Holding AB (publ)'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Critical — Revenue -97% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -57%, ROA -34.4% |
Ownership (VCRE)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +1.28% |
| Shares Outstanding | 28.16M |
| Float | 20.08M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (VCRE)
Vicore Pharma Holding AB (publ) is led by Ahmed S. Mousa (age 41), Chief Executive Officer, per Nexqual as of October 16, 2026 at 05:19 UTC.
| Chief Executive Officer | Ahmed S. Mousa (age 41) |
|---|---|
| Chief Financial Officer | Hans Jeppsson |
| Chief Operating Officer | Mikael Nygård |
| Chief Technology Officer | Helen Barker |
| Chief Scientific Officer | Rob Slack |
Major Backers & Investors (VCRE)
Notable institutional backers of Vicore Pharma Holding AB (publ) include Franklin Strategic Series-Franklin Biotechnology Discovery Fund, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 0.46% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt